Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients
暂无分享,去创建一个
Beatriz Bellosillo | Enzo Medico | Giuseppe Rospo | Valentina Motta | Antonio Avallone | Giorgio Corti | A. Bardelli | E. Medico | M. Buscarino | S. Marsoni | F. Di Nicolantonio | B. Bellosillo | S. Hobor | C. Montagut | A. Avallone | A. Budillon | F. Tatangelo | E. Valtorta | G. Siravegna | S. Veronese | A. Sartore-Bianchi | S. Siena | F. Loupakis | A. Falcone | S. Lamba | G. Rospo | G. Crisafulli | B. Mussolin | A. Cassingena | Federica Di Nicolantonio | Alberto Bardelli | Fotios Loupakis | Fabiana Tatangelo | Alfredo Budillon | C. Cremolini | Clara Montagut | Silvia Marsoni | Andrea Sartore-Bianchi | Salvatore Siena | R. Corcoran | Silvio Veronese | Simona Lamba | Giulia Siravegna | Sebastijan Hobor | Michela Buscarino | Alessio Amatu | Calogero Lauricella | Emanuele Valtorta | C. Lauricella | G. Corti | A. Amatu | A. Ponzetti | Valentina Motta | C. Antoniotti | P. Racca | Alfredo Falcone | Patrizia Racca | Benedetta Mussolin | Andrea Cassingena | Giovanni Crisafulli | Agostino Ponzetti | Chiara Cremolini | Carlotta Antoniotti | Ryan B Corcoran | Giovanni Crisafulli | Benedetta Mussolin
[1] Gonçalo R. Abecasis,et al. The Sequence Alignment/Map format and SAMtools , 2009, Bioinform..
[2] Z. Gu,et al. Comparison of Droplet Digital PCR to Real-Time PCR for Quantitative Detection of Cytomegalovirus , 2012, Journal of Clinical Microbiology.
[3] I. Nagtegaal,et al. KRAS gene amplification in colorectal cancer and impact on response to EGFR‐targeted therapy , 2013, International journal of cancer.
[4] M. Salido,et al. Emergence of Multiple EGFR Extracellular Mutations during Cetuximab Treatment in Colorectal Cancer , 2015, Clinical Cancer Research.
[5] Richard Durbin,et al. Sequence analysis Fast and accurate short read alignment with Burrows – Wheeler transform , 2009 .
[6] K. Edlund,et al. KRAS analysis in colorectal carcinoma: Analytical aspects of Pyrosequencing and allele-specific PCR in clinical practice , 2010, BMC Cancer.
[7] K. Kinzler,et al. Cancer Genome Landscapes , 2013, Science.
[8] Jeff Mellen,et al. High-Throughput Droplet Digital PCR System for Absolute Quantitation of DNA Copy Number , 2011, Analytical chemistry.
[9] S. Misale. Acquired Resistance to Anti-EGFR Therapies in Colorectal Cancer Blockade of EGFR and MEK Intercepts Heterogeneous Mechanisms of , 2014 .
[10] R. Murthy,et al. Use of research biopsies in clinical trials: are risks and benefits adequately discussed? , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] S. Fujita,et al. Panitumumab Rechallenge in Chemorefractory Patients with Metastatic Colorectal Cancer , 2013, Journal of Gastrointestinal Cancer.
[12] E. Ma,et al. Detection of KRAS mutations in colorectal cancer by high-resolution melting analysis , 2009, Journal of Clinical Pathology.
[13] M. Salto‐Tellez,et al. RAS testing of colorectal carcinoma—a guidance document from the Association of Clinical Pathologists Molecular Pathology and Diagnostics Group , 2014, Journal of Clinical Pathology.
[14] P. Angenendt,et al. Characterizing the patterns of clonal selection in circulating tumor DNA from patients with colorectal cancer refractory to anti-EGFR treatment. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.
[15] Davide Corà,et al. A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. , 2011, Cancer discovery.
[16] Peter Ulz,et al. Changes in Colorectal Carcinoma Genomes under Anti-EGFR Therapy Identified by Whole-Genome Plasma DNA Sequencing , 2014, PLoS genetics.
[17] L. Mazzucchelli,et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] Does T790M disappear? Successful gefitinib rechallenge after T790M disappearance in a patient with EGFR-mutant non-small-cell lung cancer. , 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[19] Bert Vogelstein,et al. DETECTION OF CIRCULATING TUMOR DNA IN EARLY AND LATE STAGE HUMAN MALIGNANCIES , 2014 .
[20] Kai Ye,et al. Pindel: a pattern growth approach to detect break points of large deletions and medium sized insertions from paired-end short reads , 2009, Bioinform..
[21] Enzo Medico,et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer , 2012, Nature.
[22] K. A. Palacio-Rúa,et al. Genetic analysis in APC, KRAS, and TP53 in patients with stomach and colon cancer. , 2014, Revista de gastroenterologia de Mexico.
[23] J. Tabernero,et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. , 2013, The New England journal of medicine.
[24] A. Bardelli,et al. Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] B. Neyns,et al. Successful rechallenge in two patients with BRAF-V600-mutant melanoma who experienced previous progression during treatment with a selective BRAF inhibitor. , 2012, Melanoma research.
[26] L. Diaz,et al. Liquid biopsies: genotyping circulating tumor DNA. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] A. McCullough. Comprehensive molecular characterization of human colon and rectal cancer , 2013 .
[28] Andrea Bertotti,et al. Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer. , 2013, Cancer discovery.
[29] W. Sellers,et al. Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance , 2013, Nature.
[30] Frank Diehl,et al. BEAMing: single-molecule PCR on microparticles in water-in-oil emulsions , 2006, Nature Methods.
[31] H. Nielsen,et al. Analysis of circulating tumour DNA to monitor disease burden following colorectal cancer surgery , 2015, Gut.
[32] M. Berger,et al. Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: a proof-of-principle. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.
[33] A. Bardelli,et al. Resistance to anti-EGFR therapy in colorectal cancer: from heterogeneity to convergent evolution. , 2014, Cancer discovery.
[34] R. Arceci. Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing , 2012 .
[35] Mingming Jia,et al. COSMIC: exploring the world's knowledge of somatic mutations in human cancer , 2014, Nucleic Acids Res..
[36] Antonio C. Wolff,et al. Detection of Cancer DNA in Plasma of Patients with Early-Stage Breast Cancer , 2014, Clinical Cancer Research.
[37] R. Zárate,et al. Quantitative Cell-Free Circulating BRAF Mutation Analysis by Use of Droplet Digital PCR in the Follow-up of Patients with Melanoma Being Treated with BRAF Inhibitors , 2014 .
[38] Klaus Pantel,et al. Cell-free nucleic acids as biomarkers in cancer patients , 2011, Nature Reviews Cancer.
[39] M. Okada,et al. [New response evaluation criteria in solid tumours-revised RECIST guideline (version 1.1)]. , 2009, Gan to kagaku ryoho. Cancer & chemotherapy.
[40] S. Kimura,et al. Application of a Highly Sensitive Detection System for Epidermal Growth Factor Receptor Mutations in Plasma DNA , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[41] R. Foà,et al. Simple genetic diagnosis of hairy cell leukemia by sensitive detection of the BRAF-V600E mutation. , 2012, Blood.
[42] Richard Durbin,et al. Fast and accurate long-read alignment with Burrows–Wheeler transform , 2010, Bioinform..
[43] Benjamin E. Gross,et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. , 2012, Cancer discovery.
[44] S. Serrano,et al. Evolution of heterogeneous mechanisms of acquired resistance to cetuximab-based therapy in colorectal cancer. , 2014 .
[45] P. Jänne,et al. Activation of ERBB2 Signaling Causes Resistance to the EGFR-Directed Therapeutic Antibody Cetuximab , 2011, Science Translational Medicine.
[46] M. Choti,et al. Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies , 2014, Science Translational Medicine.
[47] K. A. Palacio-Rúaa,et al. Genetic analysis in APC , KRAS , and TP 53 in patients with stomach and colon cancer , 2014 .
[48] M. Fleischhacker,et al. Circulating nucleic acids (CNAs) and cancer--a survey. , 2007, Biochimica et biophysica acta.
[49] F. López-Ríos,et al. A comparison of three methods for detecting KRAS mutations in formalin-fixed colorectal cancer specimens , 2012, British Journal of Cancer.
[50] A. Bardelli,et al. Genotyping cell-free tumor DNA in the blood to detect residual disease and drug resistance , 2014, Genome Biology.
[51] Johannes G. Reiter,et al. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers , 2012, Nature.
[52] Benjamin E. Gross,et al. Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal , 2013, Science Signaling.